A nationwide asthma management and prevention strategy to alleviate the suffering of over 15 million asthma patients in China is about to kick off, reports China Medical News. The Chinese move is part of the global campaign, Global Initiative on Asthma, jointly spearheaded by the World Health Organization and the US National Heart, Lung and Blood Institute. Targeting both doctors and patients, GINA will recommend therapy which pinpoints the best medicines for different conditions. It will aim to educate patients and their families about causes and prevention of asthma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze